Peanut allergy affects about 1 million children in the US and only 1 in 5 will outgrow this potentially life-threatening condition. Palforzia, a new medicine designed to lessen the overwhelming allergic reaction to peanuts was approved by the FDA on January 31, 2020. While this new therapy won’t enable peanut-allergic people to consume peanuts with abandon, it will significantly reduce the reaction, hopefully preventing hospitalization or worse.
This therapy will be available only through specially certified healthcare providers, health care settings, and pharmacies to patients who are enrolled in the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) program. If you or a family member has a peanut allergy, see your pediatrician, primary care physician or allergist to learn more about Palforzia.